Key facts
- Vogenx’s last known valuation is $77.0M (Jan 2022).
- It has raised $11.8M across 1 recorded rounds; the latest was Later Stage VC ($750K) in Jan 2026.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Vogenx
Funding rounds
1 roundsAbout Vogenx
Operator of a clinical-stage life science and drug development company intended to improve the lives of patients suffering from dysfunctions in human metabolism. The company targets improving the lives of people suffering from dysfunctions in human metabolism and rare diseases, enabling patients to get proper treatment.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2021
- Employees
- 5
- Website
- vogenx.com/
- Ownership
- Privately Held (backing)
Vogenx doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Vogenx shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Vogenx in its N-PORT filings yet. We sweep new filings monthly.